Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 8/20 | 0.61 |
| ▸ | KDR | P35968 | 7/20 | 0.61 |
| ▸ | SRC | P12931 | 7/20 | 0.50 |
| ▸ | ABL1 | P00519 | 5/20 | 0.48 |
| ▸ | EGFR | P00533 | 5/20 | 0.48 |
| ▸ | ABL2 | P42684 | 4/20 | 0.48 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655700 | 0.93 | RET (0.56) | RETKDRSRCABL1EGFR | |
| SCHEMBL19731250 | 0.88 | RET (0.62) | RETKDRSRCABL1EGFR | |
| Hydrochloric Acid SCHEMBL20981729 | 0.88 | RET (0.61) | RETKDRSRCABL1EGFR | |
| SCHEMBL16655766 | 0.85 | PIK3CD (0.50) | RETKDRSRCABL1EGFR | |
| SCHEMBL16655753 | 0.85 | PIK3CD (0.50) | RETKDRSRCABL1EGFR | |
| SCHEMBL16655896 | 0.82 | PIK3CD (0.49) | RETKDRSRCABL1EGFR | |
| SCHEMBL16655548 | 0.81 | RET (0.78) | RETKDRSRCABL1ATR | |
| Hydrochloric Acid SCHEMBL29588863 | 0.81 | RET (0.54) | RETKDRSRCABL1EGFR | |
| SCHEMBL19731453 | 0.80 | FGFR1 (0.70) | RETKDREGFR | |
| SCHEMBL29589295 | 0.80 | FGFR1 (0.70) | RETKDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | claimed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | claimed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | claimed |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | RET 753/4885KDR 858/4885SRC 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.